{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:20Z","timestamp":1792787300156,"version":"4.5.0"},"reference-count":62,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stiftungen zu Gunsten der Medizinischen Fakult\u00e4t","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Bavarian Cancer Research Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Wilhelm-Sander Stiftung","award":["2018.087.1"],"award-info":[{"award-number":["2018.087.1"]}]},{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"crossref","award":["DJCLS 10 R\/2023"],"award-info":[{"award-number":["DJCLS 10 R\/2023"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Else-Kr\u00f6ner-Fresenius Forschungskolleg CSP Cancer Immunotherapy","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Graduate School","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DFG","award":["451580403"],"award-info":[{"award-number":["451580403"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB 338\/1 2021-452881907"],"award-info":[{"award-number":["SFB 338\/1 2021-452881907"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Challenges to developing immunotherapies for acute myeloid leukemia (AML) include the identification of suitable target antigens due to on-target-off-leukemia toxicity. CD70, expressed on AML bulk and leukemic stem cells with limited expression on healthy cells, has emerged as a promising target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study evaluated CD70 as a target for NK-cell-based immunotherapy using a sugar-engineered antibody (PF-08046040, SEA-CD70). CD70 surface expression was assessed in primary AML samples by multiparameter flow cytometry. The cytotoxic capacity of SEA-CD70 was analyzed through antibody-dependent cellular cytotoxicity (ADCC) assays using AML cell lines, primary AML samples, and a severe combined immunodeficiency (SCID) mouse xenograft model. The effects of cytokines on CD70 expression and ADCC were investigated by exposing AML cells to conditioned medium (CM) derived from activated T cells or recombinant cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Flow cytometry revealed CD70 expression ranging from 0.2% to 89.6% (median=7.0%, n=86) in primary AML cells across genetic subgroups; this expression remained unchanged at relapse (median=3.9%, n=14). SEA-CD70 showed potent, dose-dependent cytotoxicity against AML cell lines, primary cells, and in an SCID mouse model, which correlated with CD70 expression levels. Notably, AML cells exposed to CM from activated T cells upregulated CD70. TNF-\u03b1 was identified as the driver of CD70 upregulation, translating into enhanced ADCC against AML cells (cytotoxicity w\/o TNF-\u03b1 = 17.9%\u2009vs with TNF-\u03b1 = 34.3%, n=13\u201315). Conversely, IFN-\u03b3 exposure led to reduced ADCC (cytotoxicity w\/o IFN-\u03b3 = 17.9%\u2009vs with IFN-\u03b3 = 9.2%, n=15), which is attributed to increased expression of NK inhibitory receptor ligands (HLA-ABC, HLA-E). Blocking of the corresponding inhibitory NK receptors (KIR\/CD158b and NKG2A) partially reversed this effect. Similar findings were observed with a CD33-directed antibody, indicating a universal resistance mechanism against ADCC-based immunotherapy in AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD70 is a promising target for NK cell-based immunotherapy in AML. However, IFN-\u03b3-dependent upregulation of HLA molecules on AML cells contributes to resistance to ADCC. These findings underscore the need for rationale combination strategies in clinical trials to overcome this inducible immune escape mechanism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013024","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:27Z","timestamp":1764875427000},"page":"e013024","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["TNF-\u03b1 and IFN-\u03b3 differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2568-3893","authenticated-orcid":false,"given":"Monika","family":"Sponheimer","sequence":"first","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"White","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-4807","authenticated-orcid":false,"given":"Maryam","family":"Kazerani","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maiser","sequence":"additional","affiliation":[{"name":"Faculty of Biology and Center for Molecular Biosystems (BioSysM), LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil Thore","family":"Tyborski","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Petra","family":"Rappa","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Richter","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Anthropology & Human Genomics, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Briem","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Anthropology & Human Genomics, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerulf","family":"H\u00e4nel","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Philipp","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-9952","authenticated-orcid":false,"given":"Daniel","family":"Nixdorf","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rohrbacher","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Marcinek","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Linder","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, LMU Munich Gene Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kuhl","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, LMU Munich Gene Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Piseddu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, LMU Munich Gene Center, Munich, Germany"},{"name":"Department of Medicine II, University Hospital LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Straub","sequence":"additional","affiliation":[{"name":"Bioinformatics Unit, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmann","family":"Harz","sequence":"additional","affiliation":[{"name":"Faculty of Biology and Center for Molecular Biosystems (BioSysM), LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wichmann","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maenner","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Hornung","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, LMU Munich Gene Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Leonhardt","sequence":"additional","affiliation":[{"name":"Faculty of Biology and Center for Molecular Biosystems (BioSysM), LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina H M J","family":"Van Elssen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands"},{"name":"Research Institute for Oncology and Reproduction (GROW), Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Abdelhamed","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Diolaiti","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital LMU Munich, Munich, Germany"},{"name":"Laboratory for Translational Cancer Immunology, LMU Munich Gene Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2025120411102157000_13.12.e013024.1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614359"},{"key":"2025120411102157000_13.12.e013024.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"2025120411102157000_13.12.e013024.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"2025120411102157000_13.12.e013024.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"2025120411102157000_13.12.e013024.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"2025120411102157000_13.12.e013024.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"2025120411102157000_13.12.e013024.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"2025120411102157000_13.12.e013024.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"2025120411102157000_13.12.e013024.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.5768"},{"key":"2025120411102157000_13.12.e013024.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1085978","article-title":"Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia","volume":"13","author":"Schorr","year":"2022","journal-title":"Front Immunol"},{"key":"2025120411102157000_13.12.e013024.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523548"},{"key":"2025120411102157000_13.12.e013024.12","doi-asserted-by":"publisher","DOI":"10.1309\/T903Y1FY5WKK9EEY"},{"key":"2025120411102157000_13.12.e013024.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221"},{"key":"2025120411102157000_13.12.e013024.14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152008"},{"key":"2025120411102157000_13.12.e013024.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.004"},{"key":"2025120411102157000_13.12.e013024.16","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0610351"},{"key":"2025120411102157000_13.12.e013024.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02215-y"},{"key":"2025120411102157000_13.12.e013024.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00774.x"},{"key":"2025120411102157000_13.12.e013024.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.10.009"},{"key":"2025120411102157000_13.12.e013024.20","doi-asserted-by":"publisher","DOI":"10.1038\/80877"},{"key":"2025120411102157000_13.12.e013024.21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-199634","article-title":"PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study","volume":"144","author":"Grieselhuber","year":"2024","journal-title":"Blood"},{"key":"2025120411102157000_13.12.e013024.22","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"2025120411102157000_13.12.e013024.23","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00262-023-03457-9","article-title":"Correction to: CD33 BiTE\u00ae molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells","volume":"72","author":"Marcinek","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025120411102157000_13.12.e013024.24","doi-asserted-by":"crossref","DOI":"10.1002\/pst.2399","article-title":"Experimental design considerations and statistical analyses in preclinical tumor growth inhibition studies","volume":"24","author":"Bonato","year":"2025","journal-title":"Pharm Stat"},{"key":"2025120411102157000_13.12.e013024.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-849802"},{"key":"2025120411102157000_13.12.e013024.26","doi-asserted-by":"publisher","DOI":"10.1101\/gr.176701.114"},{"key":"2025120411102157000_13.12.e013024.27","unstructured":"Andrews S . FastQC: a quality control tool for high throughput sequence data. Cambridge, United Kingdom, 2010."},{"key":"2025120411102157000_13.12.e013024.28","doi-asserted-by":"publisher","DOI":"10.14806\/ej.17.1.200"},{"key":"2025120411102157000_13.12.e013024.29","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giy059","article-title":"zUMIs - A fast and flexible pipeline to process RNA sequencing data with UMIs","volume":"7","author":"Parekh","year":"2018","journal-title":"Gigascience"},{"key":"2025120411102157000_13.12.e013024.30","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu719"},{"key":"2025120411102157000_13.12.e013024.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"2025120411102157000_13.12.e013024.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.04.004"},{"key":"2025120411102157000_13.12.e013024.33","doi-asserted-by":"crossref","unstructured":"Pires IS , Hammond PT , Irvine DJ . Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress. Advanced Therapeutics 2021;4. doi:10.1002\/adtp.202100035","DOI":"10.1002\/adtp.202100035"},{"key":"2025120411102157000_13.12.e013024.34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature New Biol"},{"key":"2025120411102157000_13.12.e013024.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8"},{"key":"2025120411102157000_13.12.e013024.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"2025120411102157000_13.12.e013024.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016200"},{"key":"2025120411102157000_13.12.e013024.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.12.007"},{"key":"2025120411102157000_13.12.e013024.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62749"},{"key":"2025120411102157000_13.12.e013024.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.11.008"},{"key":"2025120411102157000_13.12.e013024.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01315-x"},{"key":"2025120411102157000_13.12.e013024.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-50262-6","article-title":"Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab","volume":"14","author":"Lorig-Roach","year":"2024","journal-title":"Sci Rep"},{"key":"2025120411102157000_13.12.e013024.43","doi-asserted-by":"crossref","first-page":"17675","DOI":"10.18632\/oncotarget.24832","article-title":"A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies","volume":"9","author":"Vey","year":"2018","journal-title":"Oncotarget"},{"key":"2025120411102157000_13.12.e013024.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1108"},{"key":"2025120411102157000_13.12.e013024.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360255"},{"key":"2025120411102157000_13.12.e013024.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206532"},{"key":"2025120411102157000_13.12.e013024.47","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O"},{"key":"2025120411102157000_13.12.e013024.48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature New Biol"},{"key":"2025120411102157000_13.12.e013024.49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025120411102157000_13.12.e013024.50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6506"},{"key":"2025120411102157000_13.12.e013024.51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1052213","article-title":"Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis","volume":"5","author":"Andersson","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025120411102157000_13.12.e013024.52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45816"},{"key":"2025120411102157000_13.12.e013024.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100354108"},{"key":"2025120411102157000_13.12.e013024.54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002629"},{"key":"2025120411102157000_13.12.e013024.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.014"},{"key":"2025120411102157000_13.12.e013024.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447"},{"key":"2025120411102157000_13.12.e013024.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.06.034"},{"key":"2025120411102157000_13.12.e013024.58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cllc.2017.10.004","article-title":"Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer","volume":"19","author":"Ciuleanu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2025120411102157000_13.12.e013024.59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02072"},{"key":"2025120411102157000_13.12.e013024.60","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ygyno.2023.01.003","article-title":"Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer","volume":"170","author":"Herzog","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025120411102157000_13.12.e013024.61","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp314"},{"key":"2025120411102157000_13.12.e013024.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.133"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T19:10:32Z","timestamp":1764875432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-013024"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013024","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}